TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Males or non-pregnant females aged ≥ 18 years at the time of vaccination.~* Females of child-bearing potential (i.e., ovulating, pre-menopausal, not surgically sterile) must be abstinent or be willing to use a medically accepted contraceptive regimen for the duration of the On-study period. Females of child-bearing potential must return a negative urine pregnancy test result prior to vaccination with the vaccine.~Exclusion Criteria:~* Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs, chicken protein, neomycin, polymyxin, or any components of bioCSL influenza vaccines.~* Vaccination against influenza in the previous 6 months.~* Known history of Guillain-Barré Syndrome or other demyelinating disease.~* Clinical signs of active infection and/or an oral temperature of ≥ 100.4°F (38.0°C).~* A clinically significant medical condition.~* Pregnant or lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Quadrivalent Influenza Vaccine (QIV) (Type: EXPERIMENTAL): The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
- Trivalent Influenza Vaccine (TIV-1) (Type: ACTIVE_COMPARATOR): The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2014/2015 influenza season).
- Trivalent Influenza Vaccine (TIV-2) (Type: ACTIVE_COMPARATOR): The bioCSL study vaccine is a sterile, thiomersal-free suspension containing 45 mcg total hemagglutinin antigen per 0.5 mL dose (15 mcg each of the recommended influenza A (H1N1-, H3N2-like) strains and the alternate B strain for the Northern Hemisphere 2014/2015 influenza season).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Reproductive age women seeking abortion services.~* Eligible women will be in general good health and assessed by a clinician to have an intrauterine pregnancy less than 64 days L.M.P on the day mifepristone will be taken.~* Participants must be eligible for medical abortion according to clinician and clinic standards.~* In the United States, women only 18 years and older will be eligible to participate, unless the study site obtains a waiver to include minors.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- clinic administration of mifepristone (Type: NO_INTERVENTION): None
- home administration of mifepristone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. 17 to 50 years old~2. Weigh 100 lbs. or greater and have a body mass index (BMI) of 18 to 30 (inclusive)~3. Dental extraction of three or four third molars~4. Meets post-surgical pain criteria~5. Females of childbearing age must be willing to use acceptable method of birth control~Exclusion Criteria:~1. Currently pregnant or planning to be pregnant or nursing a baby~2. Known allergy to acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, as well as hydrocodone or other opioids~3. Inability to swallow whole large tablets or capsules~4. Have other conditions that the investigator feels may impact subject's safety and/or the integrity of the study~5. Use of pain medications 5 or more times per week~6. Have a history of chronic tranquilizer use, heavy drinking, or substance abuse in the last 5 years~7. History of endoscopically documented peptic ulcer disease or bleeding disorder in the last 2 years~8. Have a positive urine drug screen

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Test acetaminophen (Type: EXPERIMENTAL): Test acetaminophen 1000 mg dose
- Commercial acetaminophen (Type: ACTIVE_COMPARATOR): Commercial acetaminophen 1000 mg dose
- Commercial ibuprofen (Type: ACTIVE_COMPARATOR): Commercial ibuprofen, 400 mg dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with sickle cell disease should have one or more of the following: acute chest syndrome requiring hospitalization; nonhemorrhagic stroke or central nervous system event lasting longer than 24 hours; recurrent caso-occlusive pain or recurrent priapism; sickle neuropathy; bilateral proliferative retinopathy and major visual impairment of at least one eye; osteonecrosis of multiple joints; transfusion dependence; vaso-occlusive.~* Patients with thalassemia should have one or more of the following: transfusion dependence; iron overload; presence of 2 or more alloantibodies against red cell antigens.~Exclusion Criteria:~* Pregnancy~* Acute hepatitis~* Cardiac ejection fraction \< 30%~* Severe renal impairment~* Severe residual functional neurologic impairment~* Evidence of HIV infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing the Dulaglutide Pen and the Semaglutide Pen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes~* Self-injection naïve to all injectable treatment (for example, diabetes therapies and other medical conditions)~* Injection naïve to performing all injectable treatment (for example, diabetes therapies and other medical conditions) to others~Exclusion Criteria:~* Currently diagnosed with gestational diabetes and/or type 1 diabetes~* Cognitive or physical difficulties that could interfere with ability to understand the training, perform the injection tasks, or complete the study questionnaires as judged by the investigator~* Is a health care practitioner who is trained in giving injections

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dulaglutide Pen (Type: EXPERIMENTAL): Injection of commercial dulaglutide pen on a practice pad.
- Semaglutide Pen (Type: EXPERIMENTAL): Injection of commercial semaglutide pen on a practice pad.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who had received at least one dose of the study vaccine in the primary study~* Written informed consent will have been obtained from the subjects before the blood sampling visit of each year.

- Gender: ALL
- Minimum Age: 29 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Havrix Group (Type: EXPERIMENTAL): Subjects who received during the primary study 2 doses of Havrix™ at Day 0 and at Month 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Severe hemophilia A (\<1% FVIII:C) according to medical history~2. Male patients aged ≥12 years~3. Previous treatment with a FVIII concentrate for at least 150 exposure days (EDs)~4. Immunocompetence (CD4+ count \>200/µL)~5. Good documentation of the historical bleeding rate (at least for the 6 months preceding study start)~6. Voluntarily given, fully informed written and signed consent obtained by the patient (or parent/legal guardian in case of adolescents) before any study-related procedures are conducted~Whenever possible, the interval between the Screening Visit and the PK or Non-PK Visit should not exceed 30 days. If the 30-day interval is exceeded, determination of the CD4+ count is to be repeated and must be \>200/µL for patients to be enrolled (i.e., exclusion criterion no. 4).~Exclusion Criteria:~1. Any coagulation disorders other than hemophilia A~2. History of FVIII inhibitor activity (≥0.6 BU) or detectable FVIII inhibitory anti-bodies (≥0.6 BU using the Nijmegen modification of the Bethesda assay) at screening, as determined by the central laboratory~3. Severe liver or kidney diseases (alanine aminotransferase \[ALAT\] and aspartate transaminase \[ASAT\] levels \>5 times of upper limit of normal, creatinine\>120 µmol/L)~4. Patients receiving or scheduled to receive immunomodulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to \>10 mg/day), or similar drugs~5. Treatment with any investigational medicinal product in another interventional clinical study currently or within 4 weeks before enrollment

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All patients will receive Wilate for prophylactic treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects with severe hemophilia A (documented plasma baseline Factor VIII level \<1 %)~* \>/= 18 but \</= 65 years of age~* Previously treated with Factor VIII concentrate(s) for a minimum of 150 exposure days (as supported by the subject's medical history)~* Immunocompetent with a CD4+ lymphocyte count \> 400/mm³~* Signed informed consent from subject~Exclusion Criteria:~* Documented history of inhibitor to Factor VIII with a titer \>/= 0.6 BU (Biological Unit), by the Nijmegen modified assay. However, subjects with a maximum historical titer of \</= 1.0 BU with the classical Bethesda assay on a single measurement but with at least 3 subsequent successive negative results (\< 0.6 BU) thereafter are eligible.~* Unable to stop Factor VIII treatment to complete a minimum 72 hour washout~* Current evidence of inhibitor to Factor VIII with a titer \>/= 0.6 BU, measured at the time of screening~* Abnormal renal function (serum creatinine \> 1.5 times the upper limit of the normal range)~* Total bilirubin \> 1.5 times the upper limit of the normal range~* Active hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels \> 2 times the upper limit of the normal range)~* Any concomitant coagulation disorder other than hemophilia A (including lupus anticoagulant)~* Platelet count \< 100,000/mm³~* Within the last 3 months prior to study entry or during the study will be treated with an immunomodulating drug other than anti-retroviral chemotherapy (e.g., a interferon, steroids, rituximab, etc)~* Any subject who requires major surgery during study period. Minor procedures may be approved if discussed in advance with the medical expert.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Healthy Volunteers Investigating How Quickly and to What Extent BAY1817080 is Taken up, Distributed, Broken Down and Eliminated From the Body, as Well as the Difference Between 2 Different Types of Tablets of BAY1817080 and the Difference Between Oral Dose and Dose in the Vein

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Healthy male subject~* Age: 18 to 55 years (inclusive) at the time of informed consent and first dose of study medication~* Body mass index (BMI) above/equal to 18 and below/equal to 30 kg/m\^2 at Screening~* Body weight of at least 45 kg at Screening~Exclusion criteria:~* Presence or history of clinically relevant cardiovascular, central nervous system (CNS), hepatic, hematopoietic disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy, asthma hypoxemia, hypertension, seizures, or allergic skin rash~* Known hypersensitivity to the study drugs~* Known severe allergies or significant non-allergic drug reactions~* Febrile illness within 1 week before study drug administration~* Current or recent (within 6 months) gastrointestinal disease that would be expected to influence the absorption of drugs~* Subject has a history of cancer, except basal cell carcinoma which has been in remission for at least 5 years prior to Screening~* Poor peripheral venous access~* Regular use of medicines within 6 months prior to screening~* Clinically relevant findings in the electrocardiogram (ECG), physical examination or laboratory examination

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 - BAY1817080 Dose 1 (Type: EXPERIMENTAL): Participants will receive one single oral dose of BAY1817080 - Formulation B at dose 1 under fasted condition
- Group 2 - BAY1817080 Dose 2 (Type: EXPERIMENTAL): Participants will receive a) one single oral dose of BAY1817080 - Formulation A at dose 2 with moderate-fat, moderate-calorie meal (MF, MC); b) one single oral dose of BAY1817080 - Formulation B at dose 2 along with one intravenous (i.v.) infusion of 0.1 mg \[13C715N\]-BAY1817080; and c) one single oral dose of BAY1817080 - Formulation B at dose 2 with high-fat, high-calorie meal (HF, HC). The 3 treatments will be administered with a randomized sequence
- Group 3 - BAY1817080 Dose 3 (Type: EXPERIMENTAL): Participants will receive a) one single oral dose of BAY1817080 - Formulation B at dose 3 under fasted condition; followed by one single oral dose of BAY1817080 - Formulation A at dose 3 with MF, MC; and followed by one single oral dose of BAY1817080 - Formulation B at dose 3 with HF, HC. The 3 treatments will be administered with a fixed sequence

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria :~* Aged ≥ 6 months to \< 36 months.~* Considered to be in good health on the basis of reported medical history and limited physical examination.~* Available for the duration of the study (44 days +4 days).~* Parent/guardian is willing and able to provide informed consent.~* Parent/guardian is willing and able to meet protocol requirements.~Exclusion Criteria :~* Reported allergy to egg proteins, chicken proteins, or any other constituent of the vaccine.~* Previous history of influenza vaccination or documented history of influenza infection.~* An acute illness with or without fever (temperature \> 100.4 °F rectal) in the 72 hours preceding enrollment in the trial (defer enrollment).~* Clinically significant findings in vital signs or review of systems (investigator judgment; defer or exclude).~* Participation in any other clinical trial within 30 days prior to enrollment up to termination of the subject's participation in the study.~* Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth.~* Personal or immediate family history of congenital immune deficiency.~* Developmental delay, neurologic disorder, or seizure disorder.~* Chronic medical, congenital, or developmental disorder.~* Known human immunodeficiency virus (HIV)-positive mother.~* Prior history of Guillain-Barré syndrome.~* Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the evaluation of the vaccine.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 36 Months
- Healthy Volunteers: t

Study Arms:
- Study Group (Type: EXPERIMENTAL): Participants received 2 doses of Fluzone® vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Adding Sufentanil to Epidural Ropivacaine on Perioperative Metabolic and Stress Responses in Combined General/Epidural Anaesthesia for Geriatric Radical Retropubic Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* elective RRP for prostatic cancer scheduled in the morning (9-11 a.m.)~* patients aged more than 65 years~* ASA physical status I or II~* absence of contraindications to epidural approach~* absence of a history of chronic pain or opioid medication~Exclusion Criteria:~* contraindication to epidural catheterization

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Have a diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria and have a clinical diagnosis of probable AD according to NINCDS/ADRDA criteria~* MMSE score of ≥ 10 and ≤ 26~* The treatment naïve patient and the one who have stopped the donepezil, galantamine, huperzine A, or memantine at least 2 weeks~* Be in stable medical condition~* Have signed off informed consent form by patients or his/her legal guardian~Key Exclusion Criteria:~* Severe AD~* Patients with a history of cerebrovascular disease, Active or uncontrolled epilepsy, Active hypothyroidism, asthma, CNS infection, other Neurodegenerative disorders, an advanced, severe, progressive, or unstable medical condition~* Attending other clinical trials or taking other clinical trial drugs~* A score of \> 4 on the Modified Hachinski Ischemic Scale (MHIS);~* Patients who is using any AChEI or memantine

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- ENA713 (Type: EXPERIMENTAL): Patients had a dose escalation from 3mg/d to 12mg/d to reach individual tolerated dosage during the titration period of 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Propofol on Postoperative Nausea and Vomiting.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parturient aged between 18 - 50 years~* Elective Cesarean under spinal anesthesia~* Patients at increased risk of PONV based on Apfel score 2 or more~* ASA Class II~* Ability to give informed consent~Exclusion Criteria:~* Allergy to propofol~* ASA Class III and above~* Anti emetic drug administered 24 hrs prior to surgery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Propofol (Type: ACTIVE_COMPARATOR): Subhypnotic dose of propofol, 0.5mg/kg, 10 - 15 min before end of surgery
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline 0.9%, 10 mL , 10 - 15 min before end of surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete